Efficacy and Safety of Guselkumab for Palmoplantar Pustulosis in Korea
Author Information
Author(s): Cho Min Kyung MD, Kim Dong Hyun MD
Primary Institution: CHA Bundang Medical Center, CHA University School of Medicine
Hypothesis
What is the effectiveness and safety of guselkumab in patients with palmoplantar pustulosis who have limited responses to conventional therapies?
Conclusion
Guselkumab shows promising efficacy and safety for treating palmoplantar pustulosis in patients with limited responses to other treatments.
Supporting Evidence
- 82.4% of patients achieved a 50% improvement in disease severity after treatment.
- 58.8% of patients used concurrent systemic therapy.
- Two cases of mild injection site reactions were reported, with no treatment discontinuation.
Takeaway
This study looked at how well a medicine called guselkumab works for people with a skin condition on their hands and feet, and it found that it helps many of them feel better.
Methodology
A retrospective study analyzing the effectiveness and safety of guselkumab in 17 patients with palmoplantar pustulosis who received more than 4 cycles of treatment.
Limitations
The study is limited by the small sample size from a single center.
Participant Demographics
The participants included 4 males and 13 females, with a median age of 46 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website